Interested in training for your team? Click here to learn more

New CMS Medicare Drug Price Guidance: Navigating Price Negotiations, 340B Drugs, CMPs for Violations

Recording of a 90-minute CLE video webinar with Q&A

This program is included with the Strafford CLE Pass. Click for more information.
This program is included with the Strafford All-Access Pass. Click for more information.

Conducted on Wednesday, June 7, 2023

Recorded event now available

or call 1-800-926-7926

This CLE webinar will guide healthcare counsel on the new CMS guidance on the Medicare Drug Price Negotiation Program. The panel will examine the guidance, discussing the drug selection criteria and the negotiation process. The panel will also address other areas of guidance and offer best practices for navigating drug price negotiations.

Description

In March 2023, the CMS issued guidance related to the implementation of the Medicare Drug Price Negotiation Program. The guidance provides the criteria for the selection of the drugs subject to negotiation. Under the negotiation program, Medicare is permitted to negotiate prescription drug pricing. The guidance also provides the program's requirements.

Negotiated prices are referred to as the drug's maximum fair price (MFP). Manufacturers of drugs with MFPs must provide pharmacies and other dispensers access to the MFPs for the drugs they dispense to those enrolled in Part D plans. Similarly, Part D plans must provide their enrollees with access to the MFPs.

The guidance sets forth requirements for manufacturers subject to the 340B program and what must be provided to 340B covered entities. Further, the guidance describes the process for the issuance of CMPs for violations under the negotiation program. Manufacturers that do not comply with the program's requirements could pay a stiff price and be removed from Part D or Part B coverage and excise tax liability.

Listen as our authoritative panel of healthcare attorneys examines CMS' guidance for the Medicare Drug Price Negotiation Program. The panel will discuss the drug selection criteria and the negotiation process. The panel will also address other areas of guidance and offer best practices for navigating drug price negotiations. The panel will frame the discussion with the precedent changes to the Medicaid drug rebate program in the American Rescue Plan Act, as well as the newly announced Center for Medicare and Medicaid Innovation (CMMI) drug pricing models.

READ MORE

Outline

  1. American Rescue Plan Act
    1. Medicaid inflation rebate changes
  2. Medicare Drug Price Negotiation Program guidance
    1. Drug selection criteria
    2. Negotiation process
  3. Additional guidance
    1. Negotiations related to 340B drugs
    2. Issuance of CMPs for violations
  4. Best practices for navigating drug price negotiations
  5. What's on deck: Center for Medicare and Medicaid Innovation Models

Benefits

The panel will review these and other key issues:

  • What drug selection criteria does the new CMS guidance set forth?
  • How will this development affect drug pricing going forward?
  • How will drug negotiations change drug pricing strategies?

Faculty

Alexandre, Mary
Mimi Moll Alexandre
Partner
McDermott Will & Emery

Ms. Alexandre counsels clients across the healthcare industry with a particular focus on entities in the managed care...  |  Read More

Schnelle, Steven
Steven J. Schnelle
Partner
McDermott Will & Emery

Mr. Schnelle delivers business-focused legal solutions to investors and business operators in the US healthcare market....  |  Read More

Access Anytime, Anywhere

Strafford will process CLE credit for one person on each recording. All formats include course handouts.

To find out which recorded format will provide the best CLE option, select your state:

CLE On-Demand Video